Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Intellia Therapeutics (NTLA) Profit After Tax (2016 - 2025)

Intellia Therapeutics (NTLA) has disclosed Profit After Tax for 11 consecutive years, with -$95.8 million as the latest value for Q4 2025.

  • Quarterly Profit After Tax rose 25.69% to -$95.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$412.7 million through Dec 2025, up 20.49% year-over-year, with the annual reading at -$412.7 million for FY2025, 20.49% up from the prior year.
  • Profit After Tax for Q4 2025 was -$95.8 million at Intellia Therapeutics, up from -$101.3 million in the prior quarter.
  • The five-year high for Profit After Tax was -$46.2 million in Q1 2021, with the low at -$147.0 million in Q2 2024.
  • Average Profit After Tax over 5 years is -$107.7 million, with a median of -$110.3 million recorded in 2022.
  • The sharpest move saw Profit After Tax crashed 217.87% in 2022, then skyrocketed 31.11% in 2025.
  • Over 5 years, Profit After Tax stood at -$81.2 million in 2021, then plummeted by 39.6% to -$113.4 million in 2022, then fell by 16.54% to -$132.2 million in 2023, then grew by 2.47% to -$128.9 million in 2024, then increased by 25.69% to -$95.8 million in 2025.
  • According to Business Quant data, Profit After Tax over the past three periods came in at -$95.8 million, -$101.3 million, and -$101.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.